Biomarkers After Heart Transplantation: Nongenomic

Heart Failure Clinics

Volumn 3, Issue 1, 2007, Pages 69-81

  Dengler, Thomas J ^a   Gleissner, Christian A ^a   Klingenberg, Roland ^a   Sack, Falk Udo ^a   Schnabel, Philipp A ^a   Katus, Hugo A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GLUTATHIONE; PROCALCITONIN; TROPONIN I; TROPONIN T;

BLOOD SAMPLING; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; HEART TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW;

BIOLOGICAL MARKERS; CHEMOKINES; CYTOKINES; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; INFLAMMATION MEDIATORS; MYOCARDIUM; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; POSTOPERATIVE PERIOD; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TROPONIN;

EID: 34249691301     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2007.02.010     Document Type: Review

References (111)

1. Wang C.W., Steinhubl S.R., Castellani W.J., et al. Inability of serum myocyte death markers to predict acute cardiac allograft rejection. Transplantation 62 12 (1996) 1938-1941
2. Gash A.K., Kayne F.J., Morley D., et al. Serum myoglobin does not predict cardiac allograft rejection. J Heart Lung Transplant 13 3 (1994) 451-454
3. Uchino T., Belboul A., el-Gatit A., et al. Assessment of myocardial damage by circulating cardiac myosin light chain I after heart transplantation. J Heart Lung Transplant 13 3 (1994) 418-423
4. Laguens R.P., Argel M.I., Chambo J.G., et al. Anti-skeletal muscle glycolipid antibodies in human heart transplantation as markers of acute rejection. Correlation with endomyocardial biopsy. Transplantation 62 2 (1996) 211-216
5. Korff S., Katus H.A., and Giannitsis E. Differential diagnosis of elevated troponins. Heart 92 7 (2006) 987-993
6. Zimmermann R., Baki S., Dengler T.J., et al. Troponin T release after heart transplantation. Br Heart J 69 5 (1993) 395-398
7. Halwachs G., Iberer F., Pieber T., et al. Troponin T as a marker for posttransplantation adaptational problems of the donor heart. J Heart Lung Transplant 15 5 (1996) 451-455
8. Alexis J.D., Lao C.D., Selter J.G., et al. Cardiac troponin T: a noninvasive marker for heart transplant rejection?. J Heart Lung Transplant 17 4 (1998) 395-398
9. Walpoth B.H., Celik B., Printzen G., et al. Assessment of troponin-T for detection of clinical cardiac rejection. Transpl Int 11 Suppl 1 (1998) S502-S507
10. Labarrere C.A., Nelson D.R., Cox C.J., et al. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 284 4 (2000) 457-464
11. Mullen J.C., Bentley M.J., Scherr K.D., et al. Troponin T and I are not reliable markers of cardiac transplant rejection. Eur J Cardiothorac Surg 22 2 (2002) 233-237
12. Hsu R.B., Tsay Y.G., Lee C.M., et al. Soluble inflammatory markers in coronary sinus and peripheral blood of heart transplant recipients. Clin Transplant 17 4 (2003) 331-337
13. Carrier M., Solymoss B.C., Cartier R., et al. Cardiac troponin T and creatine kinase MB isoenzyme as biochemical markers of ischemia after heart preservation and transplantation. J Heart Lung Transplant 13 4 (1994) 696-700
14. Biagioli B., Simeone F., Marchetti L., et al. Graft functional recovery and outcome after heart transplant: is troponin I a reliable marker?. Transplant Proc 35 4 (2003) 1519-1522
15. Minami K., Omoto T., Bothig D., et al. Creatine kinase and troponin after myocardial preservation using HTK solution (Custoidol) for clinical heart transplantation. J Heart Lung Transplant 22 2 (2003) 192-194
16. Ryan J.B., Hicks M., Cropper J.R., et al. The initial rate of troponin I release post-reperfusion reflects the effectiveness of myocardial protection during cardiac allograft preservation. Eur J Cardiothorac Surg 23 6 (2003) 898-906
17. Uys C.J., Rose A.G., and Barnard C.N. The pathology of human cardiac transplantation: an assessment after 11 years' experience at Groote Schuur Hospital. S Afr Med J 56 22 (1979) 887-896
18. Winters G.L. The pathology of heart allograft rejection. Arch Pathol Lab Med 115 3 (1991) 266-272
19. Hossein-Nia M., Mascaro J., McKenna W.J., et al. Troponin T as a non-invasive marker of cardiac allograft rejection. Lancet 341 8848 (1993) 838-841
20. Dengler T.J., Zimmermann R., Braun K., et al. Elevated serum concentrations of cardiac troponin T in acute allograft rejection after human heart transplantation. J Am Coll Cardiol 32 2 (1998) 405-412
21. Chance J.J., Segal J.B., Wallerson G., et al. Cardiac troponin T and C-reactive protein as markers of acute cardiac allograft rejection. Clin Chim Acta 312 1-2 (2001) 31-39
22. Vazquez-Rodriguez J.M., Crespo-Leiro M.G., Pampin-Conde M.F., et al. Cardiac troponin T is not a marker of biopsy-proven cellular rejection. J Heart Lung Transplant 18 2 (1999) 172-177
23. Forni A., Faggian G., Luciani G.B., et al. Correlation between troponin I serum level and acute cardiac allograft rejection: a preliminary report. Transplant Proc 32 1 (2000) 167-168
24. Moran A.M., Lipshultz S.E., Rifai N., et al. Non-invasive assessment of rejection in pediatric transplant patients: serologic and echocardiographic prediction of biopsy-proven myocardial rejection. J Heart Lung Transplant 19 8 (2000) 756-764
25. Wahlander H., Kjellstrom C., and Holmgren D. Sustained elevated concentrations of cardiac troponin T during acute allograft rejection after heart transplantation in children. Transplantation 74 8 (2002) 1130-1135
26. Siaplaouras J., Thul J., Kramer U., et al. Cardiac troponin I: a marker of acute heart rejection in infant and child heart recipients?. Pediatr Transplant 7 1 (2003) 43-45
27. Gleissner C.A., Klingenberg R., Nottmeyer W., et al. Diagnostic efficiency of rejection monitoring after heart transplantation with cardiac troponin T is improved in specific patient subgroups. Clin Transplant 17 3 (2003) 284-291
28. Gleissner C.A., Zehelein J., Sack F.U., et al. Extended experience and subgroup analysis using cardiac troponin T for rejection monitoring after heart transplantation. Transplant Proc 34 6 (2002) 2178-2180
29. Faulk W.P., Labarrere C.A., Torry R.J., et al. Serum cardiac troponin-T concentrations predict development of coronary artery disease in heart transplant patients. Transplantation 66 10 (1998) 1335-1339
30. Hokl J., Cerny J., Nemec P., et al. Serum troponin T in the early posttransplant period and long-term graft function in heart recipients. Transplant Proc 33 1-2 (2001) 2018-2019
31. Dengler T.J., Zimmermann R., Tiefenbacher C.P., et al. Endothelin plasma levels in acute graft rejection after heart transplantation. J Heart Lung Transplant 14 6 Pt 1 (1995) 1057-1064
32. Schmoeckel M., Arendt R.M., Rolinski B., et al. Enhanced endothelin-1 urine excretion in patients with graft arteriosclerosis after heart transplantation. Transplant Proc 27 3 (1995) 2097-2099
33. Wexberg P., Pacher R., Rodler S., et al. Intimal hyperplasia and coronary flow reserve after heart transplantation: association with big endothelin-1. J Heart Lung Transplant 21 12 (2002) 1257-1263
34. Murthy K.S., and Makhlouf G.M. Identification of the G protein-activating domain of the natriuretic peptide clearance receptor (NPR-C). J Biol Chem 274 25 (1999) 17587-17592
35. Kenny A.J., Bourne A., and Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 291 Pt 1 (1993) 83-88
36. McGrath M.F., de Bold M.L., and de Bold A.J. The endocrine function of the heart. Trends Endocrinol Metab 16 10 (2005) 469-477
37. Wahl H.G., Graf S., Renz H., et al. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 50 6 (2004) 1071-1074
38. Ationu A., Burch M., Singer D., et al. Cardiac transplantation affects ventricular expression of brain natriuretic peptide. Cardiovasc Res 27 2 (1993) 188-191
39. Ogawa T., Linz W., Stevenson M., et al. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 93 11 (1996) 2059-2067
40. Hervas I., Arnau M.A., Almenar L., et al. Ventricular natriuretic peptide (BNP) in heart transplantation: BNP correlation with endomyocardial biopsy, laboratory and hemodynamic measures. Lab Invest 84 1 (2004) 138-145
41. O'Neill J.O., McRae III A.T., Troughton R.W., et al. Brain natriuretic peptide levels do not correlate with acute cellular rejection in De Novo orthotopic heart transplant recipients. J Heart Lung Transplant 24 4 (2005) 416-420
42. Park M.H., Scott R.L., Uber P.A., et al. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. Am J Cardiol 90 12 (2002) 1326-1329
43. Geny B., Charloux A., Lampert E., et al. Enhanced brain natriuretic peptide response to peak exercise in heart transplant recipients. J Appl Physiol 85 6 (1998) 2270-2276
44. El Gamel A., Yonan N.A., Keevil B., et al. Significance of raised natriuretic peptides after bicaval and standard cardiac transplantation. Ann Thorac Surg 63 4 (1997) 1095-1100
45. Mehra M.R., Milani R.V., Richie M.B., et al. Ventricular-vascular uncoupling increases expression of B-type natriuretic peptide in heart transplantation. Transplant Proc 36 10 (2004) 3149-3151
46. Feldman D.S., Ikonomidis J.S., Uber W.E., et al. Human B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. J Card Fail 10 4 (2004) 292-296
47. Ma K.K., Ogawa T., and de Bold A.J. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 36 4 (2004) 505-513
48. Masters R.G., Davies R.A., Veinot J.P., et al. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 100 3 (1999) 287-291
49. Ogawa T., Veinot J.P., Davies R.A., et al. Neuroendocrine profiling of humans receiving cardiac allografts. J Heart Lung Transplant 24 8 (2005) 1046-1054
50. Wu A.H., Johnson M.L., Aaronson K.D., et al. Brain natriuretic peptide predicts serious cardiac allograft rejection independent of hemodynamic measurements. J Heart Lung Transplant 24 1 (2005) 52-57
51. Mehra M.R., Uber P.A., Walther D., et al. Gene expression profiles and B-type natriuretic peptide elevation in heart transplantation: more than a hemodynamic marker. Circulation 114 1 Suppl (2006) I21-I26
52. Ambrosi P., Oddoze C., Riberi A., et al. Aminoterminal pro-brain natriuretic peptide and ventricular filling pressures in heart transplant recipients. J Heart Lung Transplant 22 7 (2003) 822-825
53. Mehra M.R., Uber P.A., Potluri S., et al. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 94 4 (2004) 454-458
54. Klingenberg R., Koch A., Gleissner C., et al. Determinants of B-type natriuretic peptide plasma levels in the chronic phase after heart transplantation. Transpl Int 18 2 (2005) 169-176
55. Ambrosi P., Oddoze C., Riberi A., et al. Usefulness of N-terminal-pro-brain natriuretic peptide levels in predicting survival in heart transplant recipients. Am J Cardiol 94 12 (2004) 1585-1587
56. Kirchhoff W., Gradaus R., Stypmann J., et al. Vasoactive peptides during long-term follow-up of patients after cardiac transplantation. J Heart Lung Transplant 23 3 (2004) 284-288
57. Cuppoletti A., Roig E., Perez-Villa F., et al. Value of NT-proBNP determinations in the follow-up of heart transplantation. Transplant Proc 37 9 (2005) 4033-4035
58. Geny B., Follenius M., Epailly E., et al. Transient reduction without normalization of brain natriuretic peptide early after heart transplantation. J Thorac Cardiovasc Surg 115 2 (1998) 473-475
59. Hammerer-Lercher A., Mair J., Antretter H., et al. B-type natriuretic peptide as a marker of allograft rejection after heart transplantation. J Heart Lung Transplant 24 9 (2005) 1444-1449
60. Gardner R.S., Chong K.S., Murday A.J., et al. N-terminal brain natriuretic peptide is predictive of death after cardiac transplantation. Heart 92 1 (2006) 121-123
61. Taylor D.O., Edwards L.B., Mohacsi P.J., et al. The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report-2003. J Heart Lung Transplant 22 6 (2003) 616-624
62. De Maria R., Zuccelli G.C., Masini S., et al. Nonspecific increase of interleukin-2 receptor serum levels during immune events in heart transplantation. Transplant Proc 21 1 Pt 1 (1989) 440-441
63. Young J.B., Windsor N.T., Smart F.W., et al. Inability of isolated soluble interleukin-2 receptor levels to predict biopsy rejection scores after heart transplantation. Transplantation 51 3 (1991) 636-641
64. Jordan S.C., Czer L., Toyoda M., et al. Serum cytokine levels in heart allograft recipients: correlation with findings on endomyocardial biopsy. J Heart Lung Transplant 12 2 (1993) 333-337
65. Grant S.C., Lamb W.R., Brooks N.H., et al. Serum cytokines in human heart transplant recipients. Is there a relationship to rejection?. Transplantation 62 4 (1996) 480-491
66. Abdallah A.N., Billes M.A., Attia Y., et al. Evaluation of plasma levels of tumour necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy. Eur Heart J 18 6 (1997) 1024-1029
67. Leeuwenberg J.F., Froon A.H., Vaessen L.M., et al. Soluble tumor necrosis factor-receptors are not a useful marker of acute allograft rejection: a study in patients with renal or cardiac allografts. Transpl Int 8 6 (1995) 459-465
68. Kimball P.M., Radovancevic B., Isom T., et al. The paradox of cytokine monitoring-predictor of immunologic activity as well as immunologic silence following cardiac transplantation. Transplantation 61 6 (1996) 909-915
69. George J.F., Kirklin J.K., Naftel D.C., et al. Serial measurements of interleukin-6, interleukin-8, tumor necrosis factor-alpha, and soluble vascular cell adhesion molecule-1 in the peripheral blood plasma of human cardiac allograft recipients. J Heart Lung Transplant 16 10 (1997) 1046-1053
70. Fyfe A., Daly P., Galligan L., et al. Coronary sinus sampling of cytokines after heart transplantation: evidence for macrophage activation and interleukin-4 production within the graft. J Am Coll Cardiol 21 1 (1993) 171-176
71. Deng M.C., Erren M., Kammerling L., et al. The relation of interleukin-6, tumor necrosis factor-alpha, IL-2, and IL-2 receptor levels to cellular rejection, allograft dysfunction, and clinical events early after cardiac transplantation. Transplantation 60 10 (1995) 1118-1124
72. Weis M., Hartmann A., Scheuermann E.H., et al. Soluble interleukin-2-receptor levels as a marker of coronary microvascular dysfunction after heart transplantation. J Heart Lung Transplant 17 3 (1998) 294-298
73. Kao J., Kobashigawa J., Fishbein M.C., et al. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation 107 15 (2003) 1958-1961
74. Beaudeux J.L., Dorent R., Bernard M., et al. Circulating monocyte chemoattractant protein-1 in heart transplant recipients with cardiac allograft vasculopathy. Clin Biochem 35 1 (2002) 77-79
75. Kemkes B.M., Schutz A., Engelhardt M., et al. Noninvasive methods of rejection diagnosis after heart transplantation. J Heart Lung Transplant 11 4 Pt 2 (1992) S221-S231
76. Striz I., Jaresova M., Lacha J., et al. MRP 8/14 and procalcitonin serum levels in organ transplantations. Ann Transplant 6 2 (2001) 6-9
77. Zavazava N., and Kronke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 2 9 (1996) 1005-1010
78. Lindaman A., Dowden A., and Zavazava N. Soluble HLA-G molecules induce apoptosis in natural killer cells. Am J Reprod Immunol 56 1 (2006) 68-76
79. Luque J., Torres M.I., Aumente M.D., et al. Soluble HLA-G in heart transplantation: their relationship to rejection episodes and immunosuppressive therapy. Hum Immunol 67 4-5 (2006) 257-263
80. Zavazava N., Bottcher H., and Ruchholtz W.M. Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. Tissue Antigens 42 1 (1993) 20-26
81. Rose E.A., Pepino P., Barr M.L., et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant 11 3 Pt 2 (1992) S120-S123
82. Lavee J., Kormos R.L., Duquesnoy R.J., et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 10 6 (1991) 921-929 [discussion: 929-30]
83. Kobashigawa J.A., Sabad A., Drinkwater D., et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation?. Circulation 94 9 Suppl (1996) II294-II297
84. Thompson J.S., Thacker II L.R., and Takemoto S. The influence of conventional and cross-reactive group HLA matching on cardiac transplant outcome: an analysis from the United Network of Organ Sharing Scientific Registry. Transplantation 69 10 (2000) 2178-2186
85. John R., Rajasinghe H., Chen J.M., et al. Impact of current management practices on early and late death in more than 500 consecutive cardiac transplant recipients. Ann Surg 232 3 (2000) 302-311
86. Faulk W.P., Rose M., Meroni P.L., et al. Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Hum Immunol 60 9 (1999) 826-832
87. Azimzadeh A.M., Pfeiffer S., Wu G.S., et al. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant 5 10 (2005) 2349-2359
88. Okazaki T., Tanaka Y., Nishio R., et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9 12 (2003) 1477-1483
89. Suarez-Alvarez B., Lopez-Vazquez A., Diaz-Molina B., et al. The predictive value of soluble major histocompatibility complex class I chain-related molecule A (MICA) levels on heart allograft rejection. Transplantation 82 3 (2006) 354-361
90. Deng M.C., Erren M., Roeder N., et al. T-cell and monocyte subsets, inflammatory molecules, rejection, and hemodynamics early after cardiac transplantation. Transplantation 65 9 (1998) 1255-1261
91. Ballantyne C.M., Mainolfi E.A., Young J.B., et al. Relationship of increased levels of circulating intercellular adhesion molecule 1 after heart transplantation to rejection: human leukocyte antigen mismatch and survival. J Heart Lung Transplant 13 4 (1994) 597-603
92. Weigel G., Grimm M., Griesmacher A., et al. Adhesion molecule behavior during rejection and infection episodes after heart transplantation. Clin Chem Lab Med 38 5 (2000) 403-408
93. Eisenberg M.S., Chen H.J., Warshofsky M.K., et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 102 17 (2000) 2100-2104
94. Pethig K., Heublein B., Kutschka I., et al. Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitive C-reactive protein is associated with progressive luminal obstruction. Circulation 102 19 Suppl 3 (2000) III233-III236
95. Labarrere C.A., Nelson D.R., and Park J.W. Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection. Curr Opin Cardiol 16 2 (2001) 110-117
96. Hognestad A., Endresen K., Wergeland R., et al. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol 42 3 (2003) 477-482
97. Hammer S., Meisner F., Dirschedl P., et al. Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Transpl Immunol 6 4 (1998) 235-241
98. Jaresova M., Striz I., Cermakova J., et al. Serum procalcitonin concentrations in transplant patients with acute rejection and bacterial infections. Immunol Lett 69 3 (1999) 355-358
99. Galatius S., Wroblewski H., Sorensen V.B., et al. Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation?. Am Heart J 137 3 (1999) 549-554
100. Birks E.J., Hunt D., Grieve L., et al. A prospective study of plasma nitrates following human heart transplantation-relevance to myocardial function. J Heart Lung Transplant 19 4 (2000) 324-329
101. Segal J.B., Kasper E.K., Rohde C., et al. Coagulation markers predicting cardiac transplant rejection. Transplantation 72 2 (2001) 233-237
102. Holvoet P., Van Cleemput J., Collen D., et al. Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 20 3 (2000) 698-702
103. Labarrere C.A., Pitts D., Halbrook H., et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients. An immunocytochemical study. Circulation 89 4 (1994) 1599-1608
104. Warshofsky M.K., Wasserman H.S., Wang W., et al. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients. Am J Cardiol 80 2 (1997) 145-149
105. Hunt B.J., Segal H., and Yacoub M. Hemostatic changes in heart transplant recipients and their relationship to accelerated coronary sclerosis. Transplantation 55 2 (1993) 309-315
106. Meckel C.R., Anderson T.J., Mudge G.H., et al. Hemostatic/fibrinolytic predictors of allograft coronary artery disease after cardiac transplantation. Vasc Med 2 4 (1997) 306-312
107. Fiane A.E., Ueland T., Simonsen S., et al. Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation. Eur Heart J 26 16 (2005) 1660-1665
108. Zwirska-Korczala K., Zakliczynski M., Berdowska A., et al. Diagnostic validity of hepatocyte growth factor as marker for rejection in the follow-up of patients after heart transplantation. J Heart Lung Transplant 24 4 (2005) 411-415
109. Nahlawi M., Seshadri N., Boparai N., et al. Usefulness of plasma vitamin B(6), B(12), folate, homocysteine, and creatinine in predicting outcomes in heart transplant recipients. Am J Cardiol 89 7 (2002) 834-837
110. De Chiara B., Bigi R., Campolo J., et al. Blood glutathione as a marker of cardiac allograft vasculopathy in heart transplant recipients. Clin Transplant 19 3 (2005) 367-371
111. Zwirska-Korczala K., Zakliczynski M., Berdowska A., et al. Serum leptin concentration in patients after heart transplantation. Clin Transplant 20 1 (2006) 102-105